Aulos Bioscience Doses First Patient in Phase 2 Trial of Avelumab and AU-007 for NSCLC
Aulos Bioscience, an innovative immuno-oncology company focused on developing potentially groundbreaking IL-2 therapeutics to revolutionize cancer care, has announced the dosing of its first patient in a Phase 2 clinical trial. The trial evaluates the combination of AU-007, avelumab (a…
Zai Lab’s AUGTYRO® Added to China’s Reimbursement Drug List for ROS1+ NSCLC
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that China’s National Healthcare Security Administration (NHSA) has updated its 2024 National Reimbursement Drug List (NRDL) to include several of the company’s medicines. These updates expand patient access to innovative treatments across…
88% of Type 2 Diabetics Would Monitor Glucose More Consistently If Their Doctor Is ‘Watching
The 2024 National Diabetes Care Survey, a comprehensive analysis of Type 2 diabetes patients in the U.S., highlights the growing impact of cellular remote patient monitoring (RPM)™ on diabetes management. The survey reveals that an increasing number of patients are…
Oxford Nanopore and UK Biobank to Create First Epigenetic Dataset for Cancer, Dementia, and Complex Diseases
Oxford Nanopore Technologies, a leader in advanced nanopore-based molecular sensing technology, has announced a groundbreaking collaboration with UK Biobank to create the world’s first large-scale, comprehensive epigenetic dataset. Utilizing Oxford Nanopore’s cutting-edge DNA/RNA sequencing technology, the project will map the…
Sarepta and Arrowhead Pharmaceuticals Announce Global Licensing Agreement for siRNA Programs
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Under this agreement, Sarepta will gain exclusive global rights to several…
Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at RSNA 2024
Median Technologies (FR0011049824, ALMDT), a leading innovator in the development of artificial intelligence (AI)-powered medical devices for early cancer detection, is set to attend the Radiological Society of North America (RSNA) 2024 Annual Meeting, scheduled to take place in Chicago,…
Exelixis Provides Regulatory Update on Cabozantinib (CABOMETYX®) for Advanced Neuroendocrine Tumors
Exelixis, Inc. (Nasdaq: EXEL) announced that the U.S. Food and Drug Administration (FDA) has scheduled a discussion of the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. The sNDA…
Successful U.S. Remote Robotic Surgery Demo Completed with Virtual Incision, Sovato, City of Hope, and UIC
Virtual Incision, the developer of the MIRA Surgical System, and Sovato Health, the world’s only solution for enabling remote surgery, have announced the successful completion of a preclinical demonstration involving nearly 40,000 miles of combined distance. Four surgeons performed 20…
Menarini Group Presents New Data on ORSERDU® (Elacestrant) for ER+, HER2- Advanced Metastatic Breast Cancer at 2024 SABCS
The Menarini Group, a global leader in pharmaceuticals and diagnostics, along with its subsidiary Stemline Therapeutics, will present new and expanded data on ORSERDU® (elacestrant) at the 2024 San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. The company…
BioIntelliSense Study Shows Early Detection of Patient Deterioration with FDA-cleared BioButton® Device
BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, today announced the publication of peer-reviewed research in the Journal of Clinical Medicine. The study, titled “A Retrospective Observational Study of Continuous Wireless Vital Sign Monitoring via a Medical Grade…
Trustwise, Hitachi, and Partners Launch MedAssist GPT for Medical Education
Trustwise, an AI performance and risk management innovator, has partnered with Health Innovation Kent Surrey Sussex (Health Innovation KSS), Hitachi Digital Services, and Further to co-develop MedAssist GPT, a generative AI application designed to enhance medical education. The tool, leveraging…
Foresight Diagnostics to Present CLARITY™ MRD Data at 2024 San Antonio Breast Cancer Symposium
Foresight Diagnostics (Foresight) today revealed new data from its ultra-sensitive Foresight CLARITY™ minimal residual disease (MRD) platform in early-stage breast cancer, which will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) later this month. Foresight Diagnostics and…